paroxetine has been researched along with risperidone in 58 studies
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 9 (15.52) | 18.2507 |
2000's | 30 (51.72) | 29.6817 |
2010's | 18 (31.03) | 24.3611 |
2020's | 1 (1.72) | 2.80 |
Authors | Studies |
---|---|
Topliss, JG; Yoshida, F | 1 |
Gao, F; Lombardo, F; Obach, RS; Shalaeva, MY | 1 |
Benz, RD; Contrera, JF; Kruhlak, NL; Matthews, EJ; Weaver, JL | 1 |
Bilter, GK; Dias, J; Huang, Z; Keon, BH; Lamerdin, J; MacDonald, ML; Michnick, SW; Minami, T; Owens, S; Shang, Z; Westwick, JK; Yu, H | 1 |
Bergström, F; Giordanetto, F; Rehngren, M; Tunek, A; Wan, H | 1 |
Lombardo, F; Obach, RS; Waters, NJ | 1 |
Ahman, M; Holmén, AG; Wan, H | 1 |
Chupka, J; El-Kattan, A; Feng, B; Miller, HR; Obach, RS; Troutman, MD; Varma, MV | 1 |
Cleves, AE; Jain, AN; Kirshner, D; Langham, JJ; Spitzer, R | 1 |
Barnes, JC; Bradley, P; Day, NC; Fourches, D; Reed, JZ; Tropsha, A | 1 |
Fisk, L; Greene, N; Naven, RT; Note, RR; Patel, ML; Pelletier, DJ | 1 |
Ekins, S; Williams, AJ; Xu, JJ | 1 |
Alelyunas, YW; Bui, K; Empfield, JR; McCarthy, D; Pelosi-Kilby, L; Shen, C; Spreen, RC | 1 |
Boriss, H; Braggio, S; Corbioli, S; Fontana, S; Helmdach, L; Longhi, R; Schiller, J; Vinco, F | 1 |
Claxton, CR; Curran, RE; Harradine, PJ; Hutchison, L; Littlewood, P; Martin, IJ | 1 |
Dalvie, D; Loi, CM; Smith, DA | 1 |
Brown, AM; Bruening-Wright, A; Kramer, J; Kuryshev, YA; Myatt, G; Obejero-Paz, CA; Verducci, JS | 1 |
Bellman, K; Knegtel, RM; Settimo, L | 1 |
Chen, M; Hu, C; Suzuki, A; Thakkar, S; Tong, W; Yu, K | 1 |
García-Rodríguez, JA; Muñoz-Bellido, JL; Muñoz-Criado, S | 1 |
Sitarz, WE | 1 |
Green, AI; Patel, JK; Salzman, C; Tsuang, MT | 1 |
O'Connor, M; Silver, H | 1 |
Friedman, JH | 1 |
Agid, O; Lerer, B | 1 |
Nelson, JC; Ostroff, RB | 1 |
Draper, B; Meares, S | 1 |
Bottlender, R; Möller, HJ | 1 |
Saria, A; Schatz, DS | 1 |
Hamilton, S; Malone, K | 1 |
Baldessarini, RJ; Tarazi, FI; Zhang, K | 1 |
Hansen, L; Wilkinson, DG | 1 |
Ancione, M; Avenoso, A; Facciolà, G; Madia, A; Scordo, MG; Spina, E | 1 |
Gillman, PK | 1 |
Hubrich-Ungureanu, P; Knopf, U; Thome, J | 1 |
Ismail, M; Lyster, G | 1 |
Ohmori, T; Sumitani, S | 1 |
Shelton, RC; Stahl, SM | 1 |
Tsai, JH; Yang, P | 1 |
Girardi, P; Kotzalidis, GD; Lazanio, S; Manfredi, G; Ruberto, A; Tatarelli, R | 1 |
Furukori, H; Kaneko, S; Nakagami, T; Saito, M; Yasui-Furukori, N | 1 |
Goto, M; Kaji, K; Kakihara, S; Nakamura, J; Shinkai, K; Ueda, N; Yamada, Y; Yoshimura, R | 1 |
Al Chekakie, MO; Ketz, JM; Whinney, CM | 1 |
Harada, M; Kubo, H; Ohmori, T; Sumitani, S | 1 |
Alacqua, M; Arcoraci, V; Calarese, T; Di Vita, G; Gagliano, C; Germanò, E; Magazù, A; Spina, E; Trifirò, G | 1 |
Murphy, D; Yui, K | 1 |
Hayashida, K; Kiriike, N; Matsunaga, H; Nagata, T; Ohya, K; Stein, DJ | 1 |
Cohen, LJ; Galynker, II; Prosser, JM; Steele, A; Yard, S | 1 |
Daliahu, Y; Melamed, Y; Paleacu, D | 1 |
LeBlanc, SR; Ovanessian, MM; Parikh, SV | 1 |
Calabrese, JR; Cao, L; Chen, J; Cui, X; Fang, Y; Gao, K; Hong, W; Jiang, K; Wang, Y; Wu, Z; Xu, Y; Yi, Z; Yuan, C | 1 |
Gurwitz, D; Morag, A; Oved, K | 1 |
Cao, L; Chen, J; Fang, Y; Hong, W; Peng, D; Wu, Z; Yuan, C; Zhang, C | 1 |
Garabadu, D; Joy, KP; Krishnamurthy, S | 1 |
Ahmad, A; Garabadu, D; Krishnamurthy, S | 1 |
Ago, Y; Hasebe, S; Hashimoto, H; Matsuda, T; Nishiyama, S; Oka, S; Takuma, K | 1 |
Baroni, M; Boccardi, V; Ercolani, S; Giordano, M; Longo, A; Mecocci, P; Paolacci, L; Ruggiero, C | 1 |
Abbara, C; Briet, M; Drevin, G; Jousset, N; Picard, N | 1 |
2 review(s) available for paroxetine and risperidone
Article | Year |
---|---|
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Drug Labeling; Humans; Pharmaceutical Preparations; Risk | 2016 |
[The treatment of OCD].
Topics: Antipsychotic Agents; Behavior Therapy; Clomipramine; Drug Therapy, Combination; Fluvoxamine; Humans; Monoamine Oxidase Inhibitors; Obsessive-Compulsive Disorder; Paroxetine; Risperidone; Selective Serotonin Reuptake Inhibitors | 2003 |
8 trial(s) available for paroxetine and risperidone
Article | Year |
---|---|
Risperidone augmentation of selective serotonin reuptake inhibitors in major depression.
Topics: Adult; Aged; Ambulatory Care; Antipsychotic Agents; Depressive Disorder; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Therapy, Combination; Female; Fluoxetine; Humans; Male; Middle Aged; Paroxetine; Psychiatric Status Rating Scales; Risperidone; Selective Serotonin Reuptake Inhibitors; Serotonin Antagonists; Treatment Outcome | 1999 |
Risperidone and paroxetine given singly and in combination for bipolar depression.
Topics: Adult; Anticonvulsants; Antipsychotic Agents; Bipolar Disorder; Double-Blind Method; Drug Administration Schedule; Drug Therapy, Combination; Female; Humans; Lithium; Male; Paroxetine; Psychiatric Status Rating Scales; Risperidone; Selective Serotonin Reuptake Inhibitors; Severity of Illness Index; Treatment Outcome | 2004 |
Dose-dependent interaction of paroxetine with risperidone in schizophrenic patients.
Topics: Adult; Aged; Antidepressive Agents, Second-Generation; Antipsychotic Agents; Dose-Response Relationship, Drug; Drug Interactions; Female; Humans; Isoxazoles; Male; Middle Aged; Paliperidone Palmitate; Paroxetine; Pyrimidines; Risperidone; Schizophrenia | 2005 |
Risperidone in the treatment of psychotic depression.
Topics: Adult; Aged; Analysis of Variance; Antidepressive Agents; Antipsychotic Agents; Depression; Dose-Response Relationship, Drug; Drug Therapy, Combination; Female; Homovanillic Acid; Humans; Male; Methoxyhydroxyphenylglycol; Middle Aged; Paroxetine; Psychiatric Status Rating Scales; Psychotic Disorders; Risperidone; Time Factors | 2006 |
A long-term trial of the effectiveness and safety of atypical antipsychotic agents in augmenting SSRI-refractory obsessive-compulsive disorder.
Topics: Adult; Ambulatory Care; Antipsychotic Agents; Benzodiazepines; Body Mass Index; Cognitive Behavioral Therapy; Combined Modality Therapy; Dibenzothiazepines; Drug Resistance; Drug Therapy, Combination; Female; Fluvoxamine; Follow-Up Studies; Humans; Long-Term Care; Male; Obsessive-Compulsive Disorder; Olanzapine; Paroxetine; Quetiapine Fumarate; Risperidone; Selective Serotonin Reuptake Inhibitors; Treatment Outcome; Young Adult | 2009 |
A comparison of low-dose risperidone to paroxetine in the treatment of panic attacks: a randomized, single-blind study.
Topics: Adult; Dose-Response Relationship, Drug; Double-Blind Method; Drug Administration Schedule; Female; Humans; Male; Outcome Assessment, Health Care; Panic Disorder; Paroxetine; Psychiatric Status Rating Scales; Risperidone; Severity of Illness Index; Single-Blind Method; Treatment Outcome; Young Adult | 2009 |
A pilot study of the efficacy and safety of paroxetine augmented with risperidone, valproate, buspirone, trazodone, or thyroid hormone in adult Chinese patients with treatment-resistant major depression.
Topics: Buspirone; China; Depressive Disorder, Major; Double-Blind Method; Drug Resistance; Drug Therapy, Combination; Female; Follow-Up Studies; Humans; Male; Paroxetine; Pilot Projects; Psychiatric Status Rating Scales; Remission Induction; Risperidone; Selective Serotonin Reuptake Inhibitors; Thyroid Hormones; Trazodone; Valproic Acid | 2011 |
Difference in remission in a Chinese population with anxious versus nonanxious treatment-resistant depression: a report of OPERATION study.
Topics: Adolescent; Adult; Aged; Antidepressive Agents; Anxiety Disorders; Buspirone; China; Comorbidity; Cyclohexanols; Depressive Disorder, Major; Depressive Disorder, Treatment-Resistant; Double-Blind Method; Female; Humans; Male; Middle Aged; Paroxetine; Remission Induction; Risperidone; Treatment Outcome; Venlafaxine Hydrochloride; Young Adult | 2013 |
48 other study(ies) available for paroxetine and risperidone
Article | Year |
---|---|
QSAR model for drug human oral bioavailability.
Topics: Administration, Oral; Biological Availability; Humans; Models, Biological; Models, Molecular; Pharmaceutical Preparations; Pharmacokinetics; Structure-Activity Relationship | 2000 |
Prediction of human volume of distribution values for neutral and basic drugs. 2. Extended data set and leave-class-out statistics.
Topics: Algorithms; Blood Proteins; Half-Life; Humans; Hydrogen-Ion Concentration; Models, Biological; Pharmaceutical Preparations; Pharmacokinetics; Protein Binding; Statistics as Topic; Tissue Distribution | 2004 |
Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.
Topics: Adverse Drug Reaction Reporting Systems; Artificial Intelligence; Computers; Databases, Factual; Drug Prescriptions; Drug-Related Side Effects and Adverse Reactions; Endpoint Determination; Models, Molecular; Quantitative Structure-Activity Relationship; Software; United States; United States Food and Drug Administration | 2004 |
Identifying off-target effects and hidden phenotypes of drugs in human cells.
Topics: Bacterial Proteins; Cell Line; Cell Proliferation; Cluster Analysis; Drug Design; Drug Evaluation, Preclinical; Genetics; Humans; Luminescent Proteins; Molecular Structure; Phenotype; Recombinant Fusion Proteins; Signal Transduction; Structure-Activity Relationship | 2006 |
High-throughput screening of drug-brain tissue binding and in silico prediction for assessment of central nervous system drug delivery.
Topics: Animals; Brain; Central Nervous System Agents; Dialysis; Hydrophobic and Hydrophilic Interactions; In Vitro Techniques; Mice; Models, Statistical; Protein Binding; Quantitative Structure-Activity Relationship; Rats | 2007 |
Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
Topics: Blood Proteins; Half-Life; Humans; Hydrogen Bonding; Infusions, Intravenous; Pharmacokinetics; Protein Binding | 2008 |
Relationship between brain tissue partitioning and microemulsion retention factors of CNS drugs.
Topics: Brain; Central Nervous System; Chromatography, Liquid; Emulsions; Mass Spectrometry | 2009 |
Physicochemical determinants of human renal clearance.
Topics: Humans; Hydrogen Bonding; Hydrogen-Ion Concentration; Hydrophobic and Hydrophilic Interactions; Kidney; Metabolic Clearance Rate; Molecular Weight | 2009 |
Physical binding pocket induction for affinity prediction.
Topics: Binding Sites; Ligands; Models, Molecular; Neural Networks, Computer; Peptide Fragments; Protein Binding; Receptor, Serotonin, 5-HT1A | 2009 |
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.
Topics: Animals; Chemical and Drug Induced Liver Injury; Cluster Analysis; Databases, Factual; Humans; MEDLINE; Mice; Models, Chemical; Molecular Conformation; Quantitative Structure-Activity Relationship | 2010 |
Developing structure-activity relationships for the prediction of hepatotoxicity.
Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Humans; Structure-Activity Relationship; Tetracyclines; Thiophenes | 2010 |
A predictive ligand-based Bayesian model for human drug-induced liver injury.
Topics: Bayes Theorem; Chemical and Drug Induced Liver Injury; Humans; Ligands | 2010 |
Experimental solubility profiling of marketed CNS drugs, exploring solubility limit of CNS discovery candidate.
Topics: Central Nervous System Agents; Drug Evaluation, Preclinical; Hydrogen-Ion Concentration; Pharmaceutical Preparations; Solubility | 2010 |
Brain tissue binding of drugs: evaluation and validation of solid supported porcine brain membrane vesicles (TRANSIL) as a novel high-throughput method.
Topics: Absorption; Albumins; Animals; Brain; Brain Chemistry; Cell Membrane; Chromatography, High Pressure Liquid; Drug Evaluation, Preclinical; In Vitro Techniques; Lipids; Male; Microdialysis; Pharmaceutical Preparations; Protein Binding; Rats; Spectrometry, Mass, Matrix-Assisted Laser Desorption-Ionization; Swine; Tissue Distribution | 2011 |
Control and measurement of plasma pH in equilibrium dialysis: influence on drug plasma protein binding.
Topics: Animals; Blood Proteins; Buffers; Carbon Dioxide; Chemical Phenomena; Dialysis; Dogs; Drug Evaluation, Preclinical; Humans; Hydrogen-Ion Concentration; Macaca fascicularis; Mice; Osmolar Concentration; Pharmaceutical Preparations; Protein Binding; Rats; Reproducibility of Results | 2011 |
Which metabolites circulate?
Topics: Humans; Metabolic Clearance Rate; Pharmaceutical Preparations | 2013 |
MICE models: superior to the HERG model in predicting Torsade de Pointes.
Topics: ERG1 Potassium Channel; Ether-A-Go-Go Potassium Channels; Humans; Models, Theoretical; Patch-Clamp Techniques; Predictive Value of Tests; Torsades de Pointes | 2013 |
Comparison of the accuracy of experimental and predicted pKa values of basic and acidic compounds.
Topics: Chemistry, Pharmaceutical; Forecasting; Hydrogen-Ion Concentration; Pharmaceutical Preparations; Random Allocation | 2014 |
In-vitro activity of psychiatric drugs against Corynebacterium urealyticum (Corynebacterium group D2).
Topics: 1-Naphthylamine; Amoxicillin; Anti-Bacterial Agents; Antidepressive Agents; Cefotaxime; Corynebacterium; Drug Therapy, Combination; Gentamicins; Microbial Sensitivity Tests; Paroxetine; Risperidone; Serotonin Antagonists; Sertraline; Teicoplanin; Vancomycin | 1996 |
Comment: delayed risperidone-induced neuroleptic malignant syndrome.
Topics: Antimanic Agents; Drug Interactions; Humans; Lithium Chloride; Neuroleptic Malignant Syndrome; Paroxetine; Risperidone; Selective Serotonin Reuptake Inhibitors; Serotonin Antagonists | 1996 |
Chronic schizophrenia: response to clozapine, risperidone, and paroxetine.
Topics: Chronic Disease; Clozapine; Drug Therapy, Combination; Humans; Middle Aged; Paroxetine; Risperidone; Schizophrenia | 1997 |
Adding risperidone to selective serotonin reuptake inhibitor improves chronic depression.
Topics: Adult; Depressive Disorder; Drug Therapy, Combination; Female; Fluoxetine; Humans; Middle Aged; Paroxetine; Risperidone; Selective Serotonin Reuptake Inhibitors; Serotonin Antagonists | 1998 |
Rapid onset tardive dyskinesia ("fly catcher tongue") in a neuroleptically naive patient induced by risperidone.
Topics: Adult; Antidepressive Agents, Second-Generation; Antipsychotic Agents; Dyskinesia, Drug-Induced; Humans; Male; Mastication; Paranoid Disorders; Paroxetine; Risperidone; Tongue | 1998 |
Risperidone augmentation of paroxetine in a case of severe, treatment-refractory obsessive-compulsive disorder without comorbid psychopathology.
Topics: Adult; Comorbidity; Dopamine Antagonists; Drug Administration Schedule; Drug Therapy, Combination; Humans; Male; Obsessive-Compulsive Disorder; Paroxetine; Psychiatric Status Rating Scales; Risperidone; Selective Serotonin Reuptake Inhibitors; Treatment Outcome | 1999 |
Treatment of vocally disruptive behaviour of multifactorial aetiology.
Topics: Aged; Akathisia, Drug-Induced; Behavior Therapy; Dementia; Depression; Female; Homes for the Aged; Humans; Mental Disorders; Noise; Nursing Homes; Paroxetine; Patient Compliance; Physical Therapy Modalities; Psychomotor Agitation; Restraint, Physical; Risperidone; Verbal Behavior | 1999 |
Negative symptoms due to sleep apnea syndrome in a patient with a delusional disorder.
Topics: Antidepressive Agents, Second-Generation; Antimanic Agents; Antipsychotic Agents; Delusions; Haloperidol; Humans; Male; Middle Aged; Paroxetine; Psychiatric Status Rating Scales; Risperidone; Severity of Illness Index; Sleep Apnea Syndromes | 1999 |
Simultaneous determination of paroxetine, risperidone and 9-hydroxyrisperidone in human plasma by high-performance liquid chromatography with coulometric detection.
Topics: Chromatography, High Pressure Liquid; Colorimetry; Drug Monitoring; Humans; Isoxazoles; Paliperidone Palmitate; Paroxetine; Pyrimidines; Risperidone; Spectrophotometry, Ultraviolet | 2000 |
Serotonin syndrome during treatment with paroxetine and risperidone.
Topics: Affective Disorders, Psychotic; Humans; Male; Middle Aged; Paroxetine; Risperidone; Selective Serotonin Reuptake Inhibitors; Serotonin Antagonists; Serotonin Syndrome | 2000 |
Olanzapine, quetiapine, and risperidone: long-term effects on monoamine transporters in rat forebrain.
Topics: Animals; Antipsychotic Agents; Autoradiography; Benzodiazepines; Carrier Proteins; Caudate Nucleus; Cocaine; Dibenzothiazepines; Dopamine Plasma Membrane Transport Proteins; Male; Membrane Glycoproteins; Membrane Transport Proteins; Nerve Tissue Proteins; Nucleus Accumbens; Olanzapine; Paroxetine; Pirenzepine; Prosencephalon; Putamen; Quetiapine Fumarate; Radioligand Assay; Rats; Rats, Sprague-Dawley; Risperidone; Selective Serotonin Reuptake Inhibitors; Serotonin Plasma Membrane Transport Proteins; Tritium | 2000 |
Drug induced akathisia, suicidal ideation and its treatment in the elderly.
Topics: Aged; Aged, 80 and over; Akathisia, Drug-Induced; Antipsychotic Agents; Depressive Disorder; Drug Therapy, Combination; Humans; Male; Paroxetine; Risperidone; Selective Serotonin Reuptake Inhibitors | 2001 |
Plasma concentrations of risperidone and 9-hydroxyrisperidone during combined treatment with paroxetine.
Topics: Adult; Antipsychotic Agents; Cytochrome P-450 CYP2D6; Drug Interactions; Female; Humans; Isoxazoles; Male; Middle Aged; Paliperidone Palmitate; Paroxetine; Pyrimidines; Risperidone; Selective Serotonin Reuptake Inhibitors | 2001 |
Comments on "Serotonin syndrome during treatment with paroxetine and risperidone".
Topics: Humans; Paroxetine; Risperidone; Selective Serotonin Reuptake Inhibitors; Serotonin Antagonists; Serotonin Syndrome | 2001 |
[Paroxetine augmentation with risperidone in therapy-resistant depression].
Topics: Aged; Depressive Disorder, Major; Dose-Response Relationship, Drug; Drug Therapy, Combination; Female; Humans; Paroxetine; Recurrence; Risperidone; Treatment Outcome | 2001 |
Treatment of psychotic depression associated with steroid therapy in Churg-Strauss syndrome.
Topics: Adrenal Cortex Hormones; Antidepressive Agents, Second-Generation; Antipsychotic Agents; Churg-Strauss Syndrome; Cyclohexanols; Depression; Electroconvulsive Therapy; Female; Humans; Middle Aged; Paroxetine; Risperidone; Venlafaxine Hydrochloride | 2002 |
Occurrence of priapism with risperidone-paroxetine combination in an autistic child.
Topics: Adolescent; Autistic Disorder; Drug Therapy, Combination; Humans; Male; Paroxetine; Priapism; Risperidone | 2004 |
Postpartum depression without delivering a child?
Topics: Alprazolam; Anti-Anxiety Agents; Depression, Postpartum; Depressive Disorder, Major; Diagnostic and Statistical Manual of Mental Disorders; Family; Female; Humans; Hysterectomy; Middle Aged; Paroxetine; Risperidone; Selective Serotonin Reuptake Inhibitors; Serotonin Antagonists; Suicide, Attempted | 2005 |
Hypothermia in a patient receiving risperidone and paroxetine.
Topics: Aged; Antidepressive Agents, Second-Generation; Antipsychotic Agents; Dementia; Female; Humans; Hypothermia; Paroxetine; Risperidone | 2006 |
Proton magnetic resonance spectroscopy reveals an abnormality in the anterior cingulate of a subgroup of obsessive-compulsive disorder patients.
Topics: Adult; Antipsychotic Agents; Aspartic Acid; Basal Ganglia; Benzodiazepines; Dominance, Cerebral; Dose-Response Relationship, Drug; Drug Therapy, Combination; Energy Metabolism; Female; Fluvoxamine; Frontal Lobe; Gyrus Cinguli; Humans; Magnetic Resonance Spectroscopy; Male; Middle Aged; Nerve Net; Obsessive-Compulsive Disorder; Olanzapine; Paroxetine; Prefrontal Cortex; Risperidone; Selective Serotonin Reuptake Inhibitors; Treatment Outcome | 2007 |
Use and tolerability of newer antipsychotics and antidepressants: a chart review in a paediatric setting.
Topics: Adolescent; Antidepressive Agents; Antipsychotic Agents; Benzodiazepines; Child; Citalopram; Drug Utilization Review; Female; Fluoxetine; Humans; Hyperprolactinemia; Italy; Male; Medical Records; Mental Disorders; Olanzapine; Paroxetine; Practice Patterns, Physicians'; Retrospective Studies; Risperidone; Sertraline; Treatment Outcome | 2008 |
[Cerebral physiopathology and treatment of Asperger disorder].
Topics: Adolescent; Adult; Asperger Syndrome; Brain; Child; Child, Preschool; Fatty Acids, Unsaturated; Female; Humans; Male; Paroxetine; Risperidone; Serotonin Antagonists | 2008 |
Narcolepsy and psychotic states--a case report.
Topics: Antipsychotic Agents; Benzhydryl Compounds; Cataplexy; Central Nervous System Stimulants; Comorbidity; Drug Therapy, Combination; Female; Hallucinations; Hospitalization; Humans; Modafinil; Narcolepsy; Paroxetine; Psychotic Disorders; Referral and Consultation; Risperidone; Selective Serotonin Reuptake Inhibitors; Sleep Paralysis; Young Adult | 2009 |
Advancing bipolar disorder: key lessons from the Systematic Treatment Enhancement Program for Bipolar Disorder (STEP-BD).
Topics: Anticonvulsants; Antidepressive Agents, Second-Generation; Antipsychotic Agents; Anxiety Disorders; Attention Deficit Disorder with Hyperactivity; Bipolar Disorder; Bupropion; Combined Modality Therapy; Comorbidity; Database Management Systems; Humans; Inositol; Lamotrigine; Multicenter Studies as Topic; Paroxetine; Psychotherapy, Brief; Randomized Controlled Trials as Topic; Recurrence; Research Design; Risperidone; Smoking; Substance-Related Disorders; Suicide; Treatment Outcome; Triazines; United States; Vitamin B Complex | 2010 |
Sex differences in human lymphoblastoid cells sensitivities to antipsychotic drugs.
Topics: Anti-Inflammatory Agents; Antidepressive Agents; Antineoplastic Agents; Antipsychotic Agents; Cell Division; Cell Survival; Cells, Cultured; Cytostatic Agents; Depressive Disorder, Major; Dose-Response Relationship, Drug; Drug Resistance; Dystonic Disorders; Female; Haloperidol; Humans; Lymphocytes; Male; Paroxetine; Risperidone; Schizophrenia; Sex Characteristics; Sex Distribution | 2013 |
Risperidone ameliorates post-traumatic stress disorder-like symptoms in modified stress re-stress model.
Topics: Animals; Antidepressive Agents, Second-Generation; Antipsychotic Agents; Brain; Corticosterone; Disease Models, Animal; Dose-Response Relationship, Drug; Drug Administration Schedule; Immobility Response, Tonic; Male; Maze Learning; Paroxetine; Rats; Risperidone; Stress Disorders, Post-Traumatic; Swimming; Time Factors | 2013 |
Risperidone Attenuates Modified Stress-Re-stress Paradigm-Induced Mitochondrial Dysfunction and Apoptosis in Rats Exhibiting Post-traumatic Stress Disorder-Like Symptoms.
Topics: Animals; Antidepressive Agents, Second-Generation; Antipsychotic Agents; Apoptosis; Brain; Corticosterone; Male; Maze Learning; Mitochondria; Paroxetine; Rats; Risperidone; Stress Disorders, Post-Traumatic | 2015 |
Pharmacological profile of encounter-induced hyperactivity in isolation-reared mice.
Topics: Animals; Animals, Outbred Strains; Benzimidazoles; Bridged Bicyclo Compounds, Heterocyclic; Desipramine; Duloxetine Hydrochloride; Fluvoxamine; Hydroxycorticosteroids; Idazoxan; Indoles; Male; Mice; Motor Activity; Neuropsychological Tests; Oxazines; Paroxetine; Piperazines; Psychotropic Drugs; Pyridines; Risperidone; Ritanserin; Social Behavior; Social Isolation; Sulfonamides; Venlafaxine Hydrochloride | 2015 |
Anticholinergic Burden and Functional Status in Older People with Cognitive Impairment: Results from the Regal Project.
Topics: Activities of Daily Living; Aged; Aged, 80 and over; Alzheimer Disease; Cholinergic Antagonists; Cognitive Dysfunction; Cross-Sectional Studies; Female; Hospitalization; Humans; Italy; Longitudinal Studies; Male; Memory; Outpatients; Paroxetine; Risperidone; Trazodone | 2017 |
Pitfalls and challenges associated with phenoconversion in forensic toxcicology.
Topics: Adult; Cytochrome P-450 CYP2C19; Cytochrome P-450 CYP2D6; Forensic Toxicology; Heterozygote; Humans; Male; Paroxetine; Pharmacogenetics; Phenotype; Risperidone; Serotonin Agents; Substance-Related Disorders; Venlafaxine Hydrochloride | 2021 |